Australia's most trusted
source of pharma news
Friday, 18 April 2025
Posted 14 April 2025 AM
Biogen is in danger of losing its monopoly on multiple sclerosis treatment Tysabri, threatening the company's major PBS revenue source.
The latest TGA registrations show generic and biosimilar major, Sandoz, has lobbed the first biosimilar for natalizumab (Tyruko) into the Australian market, aiming straight at Biogen's $38.74 million franchise.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.